TLIS News and Press, Talis Biomedical Corporation From 08/02/22

REDWOOD CITY, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today provided a business...

Baker Brothers’ 13F portfolio value decreased from $20.55B to $17.40B this quarter. Horizon Therapeutics was increased while decreasing Legend Biotech. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to almost 68% of the portfolio. ...

Talis Biomedical Corporation (TLIS) Q1 2022 Earnings Conference Call May10, 2022, 04:30PM ET Company Participants Emily Faucette - SVP-Corporate Communications and IR Rob Kelley - CEO Roger Moody - CFO Conference Call Participants Rachel Vatnsdal - JPMorgan Derik De Bruin - Bank of America Ma...

Image source: The Motley Fool. Talis Biomedical Corporation (NASDAQ: TLIS) Q1 2022 Earnings Call May 10, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Talis Biomedical Corporation (TLIS) Q1 2022 Earnings Call Tran...

Talis Biomedical press release (NASDAQ:TLIS): Q1 Net Loss of $33.1M. Revenue of $3.2M (-54.3% Y/Y). Shares -11.02% AH. For further details see: Talis Biomedical Q1 revenue of $3.2M

MENLO PARK, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today reported financial res...

MENLO PARK, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation ("TLIS"), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will rep...

Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...

Talis Biomedical went public in February 2021, raising $221 million in an IPO. The firm is developing point-of-care diagnostics for infectious diseases. TLIS has experienced manufacturing delays and quality control issues which have prevented it from launching its first product. ...

Gainers: Sonnet BioTherapeutics Holdings (NASDAQ:SONN) +92%. Zhihu (NYSE:ZH) +80%. Kingsoft Cloud (NASDAQ:KC) +74%. KE Holdings (NYSE:BEKE) +61%. Dingdong Limited (NYSE:DDL) +58%. VNET Group (NASDAQ:VNET) +57%. American Rebel (NASDAQ:AREB) +61%. JOYY (NASDAQ:YY) +53%. Chindata Group (NASDAQ:C...